Drug Type Small molecule drug |
Synonyms 18-beta-Glycyrrhizic acid, Glizigen, Glycyrrhizic acid + [1] |
Target |
Action inhibitors |
Mechanism HMGB1 inhibitors(High Mobility Group Protein B1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (21 Dec 1979), |
Regulation- |
Molecular FormulaC42H62O16 |
InChIKeyLPLVUJXQOOQHMX-MOGLOQIBSA-N |
CAS Registry103000-77-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic liver disease | China | 13 Sep 2005 | |
Hepatitis C | Japan | 21 Dec 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 1 | Netherlands | - | |
Influenza, Human | Phase 1 | United States | - | |
Keratitis | Preclinical | United States | 01 May 2016 | |
HIV Infections | Preclinical | Russia | 01 Jan 2003 |
Not Applicable | - | - | Glycyrrhizin (GL) | sahhqwmcyv(apnyyjtyck) = vtrhsgftus quszjwzgga (zpbkbygyih ) | - | 01 Apr 2011 | |
(Control (no treatment)) | sahhqwmcyv(apnyyjtyck) = dyntutpaaq quszjwzgga (zpbkbygyih ) |